These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33489819)

  • 1. Decade in review: a new era for RET-rearranged lung cancers.
    Choudhury NJ; Drilon A
    Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
    Clark L; Fisher G; Brook S; Patel S; Arkenau HT
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: identification of
    Ma J; Wang B; Meng E; Meng X
    Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Desilets A; Repetto M; Yang SR; Sherman EJ; Drilon A
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627175
    [No Abstract]   [Full Text] [Related]  

  • 7. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
    Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
    Front Oncol; 2021; 11():704084. PubMed ID: 34497761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET kinase alterations in targeted cancer therapy.
    Liu X; Hu X; Shen T; Li Q; Mooers BHM; Wu J
    Cancer Drug Resist; 2020; 3(3):472-481. PubMed ID: 35582449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
    Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
    Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
    Zheng H; Chen ZS; Li J
    Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision oncology with selective RET inhibitor selpercatinib in
    Gouda MA; Subbiah V
    Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Osta BE; Ramalingam SS
    JTO Clin Res Rep; 2020 Sep; 1(3):100050. PubMed ID: 34589946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.
    O'Leary C; Xu W; Pavlakis N; Richard D; O'Byrne K
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31058838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond
    Farago AF; Azzoli CG
    Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.